- Report
- January 2025
- 250 Pages
Global
From €4478EUR$4,999USD£3,817GBP
- Report
- May 2025
- 150 Pages
Global
From €2417EUR$2,699USD£2,061GBP
- Drug Pipelines
- April 2025
- 250 Pages
Global
From €2687EUR$3,000USD£2,291GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1120EUR$1,250USD£954GBP
- Report
- December 2024
- 144 Pages
Global
From €3538EUR$3,950USD£3,016GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1791EUR$2,000USD£1,527GBP
- Drug Pipelines
- April 2025
- 50 Pages
Global
From €1344EUR$1,500USD£1,145GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1120EUR$1,250USD£954GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1120EUR$1,250USD£954GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1120EUR$1,250USD£954GBP
- Report
- April 2025
- 186 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- December 2024
Japan, United States, ... Japan, United States, Europe, Global
From €16570EUR$18,500USD£14,125GBP
- Report
- February 2025
Global, Europe, United States, ... Global, Europe, United States, Japan
From €3359EUR$3,750USD£2,863GBP
- Report
- December 2024
United States
From €2239EUR$2,500USD£1,909GBP
- Report
- December 2024
North America, Mexico, ... North America, Mexico, Canada
From €8509EUR$9,500USD£7,254GBP
- Report
- February 2025
Middle East
From €4031EUR$4,500USD£3,436GBP
- Report
- February 2025
North America, Mexico, ... North America, Mexico, Canada
From €2194EUR$2,450USD£1,871GBP
- Report
- February 2025
Europe, United Kingdom, ... Europe, United Kingdom, Spain, Italy, Germany, France
From €2553EUR$2,850USD£2,176GBP
- Report
- February 2025
United States
From €1299EUR$1,450USD£1,107GBP
- Report
- March 2024
- 102 Pages
Global
From €1523EUR$1,700USD£1,298GBP

The Factor VIII market is a segment of the hematological drugs market, which includes drugs used to treat blood-related disorders. Factor VIII is a protein that helps blood to clot, and is used to treat hemophilia A, a genetic disorder that impairs the body's ability to form blood clots. Factor VIII is typically administered intravenously, and is available in both recombinant and plasma-derived forms.
The Factor VIII market is highly competitive, with a number of companies offering products. These include Novo Nordisk, Pfizer, Bayer, CSL Behring, and Shire. Additionally, there are several smaller companies that offer Factor VIII products, such as Octapharma, Kedrion, and Biotest. Show Less Read more